Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anamorelin for idiopathic pleuroparenchymal fibroelastosis
jRCTs041220165Completed
- Sponsor
- Japan Research Foundation for Clinical Pharmacology
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anamorelin in idiopathic pleuroparenchymal fibroelastosis (IPPFE), sponsored by Japan Research Foundation for Clinical Pharmacology. Primary endpoint: Assessment of anorexia and cachexia. Started Mar 2023; status: completed.
02
Drugs
anamorelin
03
Conditions
idiopathic pleuroparenchymal fibroelastosis (IPPFE)
Beyond the preview
Go deeper on jRCTs041220165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041220165.